Suppr超能文献

血管生成素2与透析及肾移植中的心血管疾病

Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation.

作者信息

David Sascha, Kümpers Philipp, Hellpap Julian, Horn Rüdiger, Leitolf Holger, Haller Hermann, Kielstein Jan T

机构信息

Department of Medicine, Division of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany.

出版信息

Am J Kidney Dis. 2009 May;53(5):770-8. doi: 10.1053/j.ajkd.2008.11.030. Epub 2009 Mar 5.

Abstract

BACKGROUND

Accelerated atherosclerosis in patients with chronic kidney disease (CKD) is still incompletely understood. Angiopoietin 1 (Ang-1) and Ang-2 are 55-kDa antagonistic nonredundant gatekeepers of endothelial activation and thus are potential important factors in accelerated atherosclerosis. We aimed to study: (1) angiopoietin levels in patients treated by means of dialysis and kidney transplantation, (2) the association of altered angiopoietin levels with atherosclerosis, and (3) changes in altered levels after renal transplantation.

STUDY DESIGN

Cross-sectional and longitudinal observational study.

SETTING & PARTICIPANTS: 117 patients with CKD (61 hemodialysis [HD] patients, 24 peritoneal dialysis [PD] patients, and 32 renal transplant recipients) and 22 healthy controls.

PREDICTOR

Treatment by means of HD or PD or renal transplantation versus healthy controls.

OUTCOME

Serum Ang-1 and Ang-2 levels and ratio and changes in levels before and 3 months after transplantation. Correlations of angiopoietin levels with the presence and severity of coronary heart disease and peripheral arterial disease.

MEASUREMENTS

Ang-1 and Ang-2 were measured in sera by using an immunoradiometric sandwich assay and enzyme-linked immunosorbent assay, respectively. Coronary heart disease was scored by using coronary angiography, and peripheral arterial disease, by using ultrasonography.

RESULTS

Ang-1 level was decreased in HD patients compared with controls (29.1 +/- 12 versus 45.3 +/- 11.5 ng/mL; P < 0.001). In contrast, Ang-2 level was increased (HD, 8.7 +/- 0.64; PD, 6.48 +/- 8.1 ng/mL versus controls, 0.88 +/- 0.43 ng/mL; P < 0.001). Ang levels in renal transplant recipients were not different from healthy controls. Longitudinally, individual Ang-2 levels decreased after kidney transplantation (P = 0.01). In addition, in patients with CKD, Ang-2 level correlated significantly with scores of coronary heart disease (r = 0.486; P < 0.001) and peripheral arterial disease (r = 0.648; P < 0.001).

LIMITATIONS

Cross-sectional study design.

CONCLUSIONS

Circulating Ang-2 level was increased in patients treated with dialysis, although the mechanism is unknown. Kidney transplantation normalized circulating Ang-2 levels after 3 months. In addition, Ang-2 might be a mediator (and thus a marker) that accounts for accelerated atherosclerosis in dialysis patients.

摘要

背景

慢性肾脏病(CKD)患者加速性动脉粥样硬化的机制仍未完全明确。血管生成素1(Ang-1)和血管生成素2(Ang-2)是55 kDa的内皮细胞活化拮抗非冗余守门蛋白,因此可能是加速性动脉粥样硬化的重要潜在因素。我们旨在研究:(1)接受透析和肾移植治疗患者的血管生成素水平;(2)血管生成素水平改变与动脉粥样硬化的关联;(3)肾移植后血管生成素水平改变情况。

研究设计

横断面和纵向观察性研究。

研究地点及参与者

117例CKD患者(61例血液透析[HD]患者、24例腹膜透析[PD]患者和32例肾移植受者)及22例健康对照者。

预测因素

HD或PD或肾移植治疗与健康对照。

观察指标

血清Ang-1和Ang-2水平、比值及移植前和移植后3个月的水平变化。血管生成素水平与冠心病和外周动脉疾病的存在及严重程度的相关性。

测量方法

分别采用免疫放射分析夹心测定法和酶联免疫吸附测定法检测血清中的Ang-1和Ang-2。采用冠状动脉造影对冠心病进行评分,采用超声检查对外周动脉疾病进行评分。

结果

与对照组相比,HD患者的Ang-1水平降低(29.1±12对45.3±11.5 ng/mL;P<0.001)。相反,Ang-2水平升高(HD组为8.7±0.64;PD组为6.48±8.1 ng/mL,对照组为0.88±0.43 ng/mL;P<0.001)。肾移植受者的Ang水平与健康对照者无差异。纵向观察发现,肾移植后个体的Ang-2水平降低(P = 0.01)。此外,在CKD患者中,Ang-2水平与冠心病评分(r = 0.486;P<0.001)和外周动脉疾病评分(r = 0.648;P<0.001)显著相关。

局限性

横断面研究设计。

结论

透析治疗患者的循环Ang-2水平升高,但其机制尚不清楚。肾移植3个月后循环Ang-2水平恢复正常。此外,Ang-2可能是透析患者加速性动脉粥样硬化的介导因子(因而也是标志物)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验